10521-06-9

Basic information

• Product Name: Suberic anhydride
• Synonyms: Suberic anhydride;2,9-Oxonanedione;Hexanedicarboxylic anhydride
• CAS NO: 10521-06-9
• Molecular Formula: C₈H₁₂O₃
• Molecular Weight: 156.17908
• Mol File: 10521-06-9.mol
• Article Data: 27

Chemical Properties

• Melting Point: 65-66 °C
• Boiling Point: 291.0±9.0 °C(Predicted)
• Appearance: /
• Density: 1.086±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Suberic anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: Suberic anhydride(10521-06-9)
• EPA Substance Registry System: Suberic anhydride(10521-06-9)

Safety Data

• Hazardous Substances Data: 10521-06-9(Hazardous Substances Data)

Usage

General Description

Suberic anhydride, also known as octanedioic anhydride, is a chemical compound with the formula C8H12O3. It is an anhydride derivative of suberic acid and is used as a building block in the synthesis of various organic compounds, such as pharmaceuticals, agrochemicals, and polymers. It is a white solid with a pungent odor and is soluble in organic solvents. Suberic anhydride is a versatile chemical that can undergo various reactions, including esterification, amidation, and acylation, making it a valuable intermediate in the production of a wide range of products. It is also used as a crosslinking agent in the production of resins and adhesives. However, it should be handled with caution as it is a strong irritant to the eyes, skin, and respiratory system.

Upstream product

• 505-48-6 octane-1,8-dioic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 1236199-92-0 C₁₅H₂₁N₃O₅ 

Relevant articles and documents

Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron

Histone deacetylase enzymes (HDACs) are responsible for the global silencing of tumour-suppressor genes. Treatment with a histone deacetylase inhibitor (HDACi) can reverse this process and restore normal cell function. Herein, we report a small series of boron-based (boronic acid, boronate ester and closo-1,2-carborane) HDAC2 inhibitors with IC50 values in the nanomolar range. The boronate ester 4 b was the most potent compound assessed in this study (IC50=40.6±1.5 nM), followed closely by the 1,2-closo-carborane (IC50=42.9±1.5 nM). Compound 4 b exceeds the potency of the related gold-standard HDAC pan-inhibitor vorinostat (1) toward this particular HDAC isoform.

Perfluorinated HDAC inhibitors as selective anticancer agents

A series of potent histone deacetylase inhibitors is presented that incorporate alkyl or perfluorinated alkyl chains. Several new compounds show greater in vitro antiproliferative activity than the clinically approved inhibitor, SAHA. Furthermore, the new

Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors

The synthesis and biological evaluation of a novel series of compounds based on suberoylanilide hydroxamic acid (SAHA) had been designed as potential histone deacetylase inhibitors (HDACis). Molecular docking studies indicated that our derivatives had better fitting in the binding sites of HDAC8 than SAHA. Compounds 1-5 were synthesized through the synthetic routes. In biological test, compounds also showed good inhibitory activity in HDAC enzyme assay and more potent growth inhibition in human glioma cell lines (MGR2, U251, and U373). A representative compound, N3F, exhibited better inhibitory effect (HDAC, IC50 = 0.1187 μm; U251, IC50 = 0.8949 μm) and lower toxicity for human normal cells (LO2, IC50 = 172.5 μm and MRC5, IC50 = 213.6 μm) compared with SAHA (HDAC, IC50 = 0.8717 μm; U251, IC50 = 8.938 μm; LO2, IC50 = 86.52 μm and MRC5, IC50 = 81.02 μm). In addition, N3F obviously increased Beclin-1 and Caspase-3 and 9 as well as inhibited Bcl-2 in U251 cells. All of our results indicated that these SAHA cap derivatives could serve as potential lead compounds for further optimization. In addition, N3F and N2E both displayed promising profile as antitumor candidates for the treatment of human glioma.

Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer

A strategy to develop chemotherapeutic agents by combining several active groups into a single molecule as a conjugate that can modulate multiple cellular pathways may produce compounds having higher efficacy compared to that of single-target drugs. In th

Design, synthesis, and biological evaluation of HDAC degraders with CRBN E3 ligase ligands

Histone deacetylases (HDACs) play important roles in cell growth, cell differentiation, cell apoptosis, and many other cellular processes. The inhibition of different classes of HDACs has been shown to be closely related to the therapy of cancers and other diseases. In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types. One of these PROTACs, denoted 21a, with a new benzyl alcohol linker, exhibited comparably excellent HDAC inhibition activity on different HDAC classes, acceptable degradative activity, and even better in vitro anti-proliferative activities on the MM.1S cell line compared with SAHA. Moreover, we report for the first time the benzyl alcohol linker, which could also offer the potential to be used to develop more types of potent PROTACs for targeting more proteins of interest (POI).